1 Abstract
Purpose By leveraging the small-vessel specificity of velocity-selective arterial spin labeling (VSASL), we present a novel technique for measuring cerebral MicroVascular Pulsatility named MVP-VSASL.
Theory and Methods We present a theoretical model relating the pulsatile, cerebral blood flow-driven VSASL signal to the microvascular pulsatility index (PI), a widely used metric for quantifying cardiac-dependent fluctuations. The model describes the dependence of PI on bolus duration τ (an adjustable VSASL sequence parameter) and provides guidance for selecting a value of τ that maximizes the SNR of the PI measurement. The model predictions were assessed in humans using data acquired with retrospectively cardiac-gated VSASL sequences over a broad range of τ values. In vivo measurements were also used to demonstrate the feasibility of whole-brain voxel-wise PI mapping, assess intrasession repeatability of the PI measurement, and illustrate the potential of this method to explore an association with age.
Results The theoretical model showed excellent agreement to the empirical data in a gray matter region of interest (average R2 value of 0.898 ± 0.107 across six subjects). We further showed excellent intrasession repeatability of the pulsatility measurement (ICC = 0.960, p< 0.001) and the potential to characterize associations with age (r = 0.554, p = 0.021).
Conclusion We have introduced a novel, VSASL-based cerebral microvascular pulsatility technique, which may facilitate investigation of cognitive disorders where damage to the microvasculature has been implicated.
Competing Interest Statement
Drs. Han and Pfeuffer are industry co-authors and employees of Siemens Medical Solutions, Inc. and Siemens Healthineers AG, respectively.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of University of California San Diego gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
